Book contents
- Stahl’s Essential Psychopharmacology
- Additional material
- Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Preface to the Fifth Edition
- CME Information
- 1 Chemical Neurotransmission
- 2 Transporters, Receptors, and Enzymes as Targets of Psychopharmacological Drug Action
- 3 Ion Channels as Targets of Psychopharmacological Drug Action
- 4 Psychosis, Schizophrenia, and the Neurotransmitter Networks Dopamine, Serotonin, and Glutamate
- 5 Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called “Antipsychotics”
- Targeting Mesolimbic/Mesostriatal Dopamine D2 Receptors Causes Antipsychotic Actions
- Targeting Dopamine D2 Receptors in Mesolimbic/Mesostriatal and Mesocortical Pathways Causes Secondary Negative Symptoms
- Targeting Tuberoinfundibular Dopamine D2 Receptors Causes Elevation of Prolactin
- Targeting Nigrostriatal Dopamine D2 Receptors Causes Motor Side Effects
- Drugs Targeting Dopamine D2 Receptors: So-Called First Generation or Conventional “Antipsychotics”
- Drugs Targeting Serotonin 2A Receptors with or without Simultaneously Targeting Dopamine D2 Receptors
- Drugs Targeting Serotonin 1A Receptors and DOPAMINE D2 Receptors as Partial Agonists
- Links between Receptor Binding Properties of Drugs Used to Treat Psychosis and Other Therapeutic Actions and Side Effects
- Pharmacological Properties of Selected Individual First-Generation D2 Antagonists
- An Overview of the Pharmacological Properties of Individual 5HT2A/D2 Antagonists and D2/5HT1A Partial Agonists: The Pines (Peens), Many Dones and a Rone, Two Pips and a Rip
- Future Treatments for Schizophrenia
- Summary
- Contents
- 6 Mood Disorders and the Neurotransmitter Networks Norepinephrine and γ-Aminobutyric Acid (GABA)
- 7 Treatments for Mood Disorders: So-Called “Antidepressants” and “Mood Stabilizers”
- 8 Anxiety, Trauma, and Treatment
- 9 Chronic Pain and Its Treatment
- 10 Disorders of Sleep and Wakefulness and Their Treatment: Neurotransmitter Networks for Histamine and Orexin
- 11 Attention Deficit Hyperactivity Disorder and Its Treatment
- 12 Dementia: Causes, Symptomatic Treatments, and the Neurotransmitter Network Acetylcholine
- 13 Impulsivity, Compulsivity, and Addiction
- Suggested Reading and Selected References
- Index
Contents
from 5 - Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called “Antipsychotics”
- Stahl’s Essential Psychopharmacology
- Additional material
- Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Preface to the Fifth Edition
- CME Information
- 1 Chemical Neurotransmission
- 2 Transporters, Receptors, and Enzymes as Targets of Psychopharmacological Drug Action
- 3 Ion Channels as Targets of Psychopharmacological Drug Action
- 4 Psychosis, Schizophrenia, and the Neurotransmitter Networks Dopamine, Serotonin, and Glutamate
- 5 Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called “Antipsychotics”
- Targeting Mesolimbic/Mesostriatal Dopamine D2 Receptors Causes Antipsychotic Actions
- Targeting Dopamine D2 Receptors in Mesolimbic/Mesostriatal and Mesocortical Pathways Causes Secondary Negative Symptoms
- Targeting Tuberoinfundibular Dopamine D2 Receptors Causes Elevation of Prolactin
- Targeting Nigrostriatal Dopamine D2 Receptors Causes Motor Side Effects
- Drugs Targeting Dopamine D2 Receptors: So-Called First Generation or Conventional “Antipsychotics”
- Drugs Targeting Serotonin 2A Receptors with or without Simultaneously Targeting Dopamine D2 Receptors
- Drugs Targeting Serotonin 1A Receptors and DOPAMINE D2 Receptors as Partial Agonists
- Links between Receptor Binding Properties of Drugs Used to Treat Psychosis and Other Therapeutic Actions and Side Effects
- Pharmacological Properties of Selected Individual First-Generation D2 Antagonists
- An Overview of the Pharmacological Properties of Individual 5HT2A/D2 Antagonists and D2/5HT1A Partial Agonists: The Pines (Peens), Many Dones and a Rone, Two Pips and a Rip
- Future Treatments for Schizophrenia
- Summary
- Contents
- 6 Mood Disorders and the Neurotransmitter Networks Norepinephrine and γ-Aminobutyric Acid (GABA)
- 7 Treatments for Mood Disorders: So-Called “Antidepressants” and “Mood Stabilizers”
- 8 Anxiety, Trauma, and Treatment
- 9 Chronic Pain and Its Treatment
- 10 Disorders of Sleep and Wakefulness and Their Treatment: Neurotransmitter Networks for Histamine and Orexin
- 11 Attention Deficit Hyperactivity Disorder and Its Treatment
- 12 Dementia: Causes, Symptomatic Treatments, and the Neurotransmitter Network Acetylcholine
- 13 Impulsivity, Compulsivity, and Addiction
- Suggested Reading and Selected References
- Index
Summary
- Type
- Chapter
- Information
- Stahl's Essential PsychopharmacologyNeuroscientific Basis and Practical Applications, pp. 159 - 243Publisher: Cambridge University PressPrint publication year: 2022